UNIVERSITY AT BUFFALO
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1846-01-01
- Employees
- 5.2K
- Market Cap
- -
- Website
- https://www.buffalo.edu/
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 43
- Registration Number
- NCT02777073
- Locations
- ๐บ๐ธ
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
Natalizumab Temporary Discontinuation Study
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 50
- Registration Number
- NCT02775110
- Locations
- ๐บ๐ธ
Jacobs Neurological Institute, Buffalo, New York, United States
๐บ๐ธBuffalo Neuroimaging Analysis Center, Buffalo, New York, United States
Safety Study for Adolescents With Concussion
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 54
- Registration Number
- NCT02714192
- Locations
- ๐บ๐ธ
University at Buffalo, Buffalo, New York, United States
Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 103
- Registration Number
- NCT02710123
- Locations
- ๐บ๐ธ
University at Buffalo, Buffalo, New York, United States
Tecfidera Diffusion Tensor Imaging
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 115
- Registration Number
- NCT02686684
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 26
- Registration Number
- NCT02518945
- Locations
- ๐บ๐ธ
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
Liraglutide in Adolescents With Type 1 Diabetes
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 5
- Registration Number
- NCT02516657
- Locations
- ๐บ๐ธ
UBMD Pediatrics, Division of Pediatric Endocrinology, Buffalo, New York, United States
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 52
- Registration Number
- NCT02433678
- Locations
- ๐บ๐ธ
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 40
- Registration Number
- NCT02372630
- Locations
- ๐บ๐ธ
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 499
- Registration Number
- NCT02308579
ยฉ Copyright 2024. All Rights Reserved by MedPath